Literature DB >> 19880567

Ten cases of systemic lupus erythematosus related to hepatitis B vaccine.

N Agmon-Levin1, Y Zafrir, Z Paz, T Shilton, G Zandman-Goddard, Y Shoenfeld.   

Abstract

The objective of this article is to identify common and atypical features of systemic lupus erythematosus diagnosed following hepatitis B vaccination. We analyzed retrospectively the medical records of 10 systemic lupus erythematosus patients from different centers, who developed the disease following hepatitis B vaccination and determined the prevalence of different manifestations and the time association to vaccination. In this case series, 80% of the patients were female, mean age 35 +/- 9 years, of which 20% received one inoculation, 20% received two doses and 60% received all three inoculations. The mean latency period from the first hepatitis B virus immunization and onset of autoimmune symptoms was 56.3 days. All patients were diagnosed with systemic lupus erythematosus, according to the American College of Rheumatology revised criteria within 1 year. The prevalence of some systemic lupus erythematosus manifestations was typical and included involvement of the joints (100%), skin (80%), muscles (60%) and photosensitivity (30%). Other symptoms differed in this unique group of systemic lupus erythematosus patients such as low rate of kidney and hematologic involvement, and a relatively high rate of hepatitis (20%). Neurological (80%) and pulmonary (70%) symptoms were also common in this group. Data from this case-series, and previously documented cases in the literature could only show a temporal relation between hepatitis B vaccination and the appearance of systemic lupus erythematosus. Systemic lupus erythematosus related to vaccine may differ from idiopathic systemic lupus erythematosus in its clinical presentation and may resemble drug-induced systemic lupus erythematosus. Thus, physicians should be alerted to this potential association, its possible long latency period and unique presentations, and be encouraged to report and analyze these cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880567     DOI: 10.1177/0961203309345732

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice.

Authors:  E Favoino; E I Favia; L Digiglio; V Racanelli; Y Shoenfeld; F Perosa
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

2.  Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.

Authors:  S Colafrancesco; N Agmon-Levin; C Perricone; Y Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 3.  Environmental exposures and the development of systemic lupus erythematosus.

Authors:  Medha Barbhaiya; Karen H Costenbader
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

Review 4.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Authors:  Maria Vadalà; Dimitri Poddighe; Carmen Laurino; Beniamino Palmieri
Journal:  EPMA J       Date:  2017-07-20       Impact factor: 6.543

Review 5.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

Review 6.  Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature.

Authors:  N Ruhrman-Shahar; J Torres-Ruiz; P Rotman-Pikielny; Y Levy
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

7.  Human papillomavirus vaccine and systemic lupus erythematosus.

Authors:  Mariele Gatto; Nancy Agmon-Levin; Alessandra Soriano; Raffaele Manna; Ramit Maoz-Segal; Shaye Kivity; Andrea Doria; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2013-04-28       Impact factor: 3.650

8.  Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition.

Authors:  Housam Eidi; Marie-Odile David; Guillemette Crépeaux; Laetitia Henry; Vandana Joshi; Marie-Hélène Berger; Mohamed Sennour; Josette Cadusseau; Romain K Gherardi; Patrick A Curmi
Journal:  BMC Med       Date:  2015-06-17       Impact factor: 8.775

Review 9.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

10.  Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld.

Authors:  Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-05-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.